Standing together has never been so crucial for the Egis family than in these difficult times.

Egis today is among the Top50 foreign companies operating in Vietnam.

The performance of the Hungarian pharmaceutical industry in the last ‘peaceful year’ before the coronavirus epidemic was reviewed in a comprehensive analysis by Nézőpont Institute on behalf of 16 pharmaceutical companies of the Hungarian Pharmaceutical Manufacturers Association (MAGYOSZ).

On the occasion of the 25th anniversary of its establishment, KÖVET Association launched its ‘For a sustainable economy’ anniversary program and announced a tender for several categories, one of which was won by Egis on topic of environmental savings.

PharmaBoardroom is a site for senior professionals, providing global news, trends and reports relating to the pharmaceutical industry.

Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.

Following the success of Egis Russia and Egis Polska, we are proud to announce that Egis Praha has also been recognized as Best Employer at Aon Hewitt’s Employee Engagement Survey.

We have commemorated World Cancer Day.

The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.

WHO has created a six-step protocol: by applying this method, we can remove the germs, viruses, and bacteria from the surface of our hands.

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.

As research and development are fundamental pillars of our strategy Egis is deeply committed to raise students’ interest in science and help the promising young minds develop their talents. That is why we have been supporting the annual ’Scientific and Innovation Talent Recruitment Contest for Youth’ for decades. This year, Egis’ prize went to undergraduate student Hunor Sebők.

The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.

Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.

Disinfection plays an important role in reducing the risk of infection. As a responsible company, Egis supports the safe operation of pharmacies in the second wave of the coronavirus pandemic as well.

Egis Russia’s Buy for Good campaign that was carried out in 2018 won the award of ‘Best Social Projects in Russia’ in the category of medical and social projects.

In close cooperation with our employees, we're currently working on redesigning our protective clothing. Though the project is still in progress, our collaboration was already acknowledged: we were awarded the Healthy Workplaces Good Practice Award, so we can move on to the next round organized for EU countries.

Close to 300 Egis employees give blood on a regular basis at our Budapest sites. For our contribution, we received a certificate of merit from the Hungarian Red Cross.

On the occasion of the national holiday, Dr. István Hodász, CEO of Egis was granted the award ‘For the Hungarian Economy’ by Deputy Prime Minister and Minister of Finance Mihály Varga. The award is the most prestigious recognition to be given by the Minister of Finance on ministerial level for outstanding excellence and contribution to the Hungarian economy.

In close cooperation with our employees, we're currently working on redesigning our protective clothing. Though the project is still in progress, our collaboration was already acknowledged: we were awarded the Healthy Workplaces Good Practice Award, so we can move on to the next round organized for EU countries.

With programs focusing on counseling and prevention, Egis was present on the Day of Vascular Diseases.

This March marks the official start of the Hungarian Nationwide Public Health Screening Program’s special campaign: the new initiative focuses on children’s health.